Karl Dahlquist Sells 9,370 Shares of AtriCure (NASDAQ:ATRC) Stock

AtriCure, Inc. (NASDAQ:ATRC) insider Karl Dahlquist sold 9,370 shares of the stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $48.89, for a total value of $458,099.30. Following the sale, the insider directly owned 87,319 shares of the company’s stock, valued at $4,269,025.91. The trade was a 9.69% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

AtriCure Stock Down 1.2%

Shares of AtriCure stock opened at $48.68 on Wednesday. AtriCure, Inc. has a one year low of $25.36 and a one year high of $49.88. The company has a market cap of $2.48 billion, a P/E ratio of 231.82 and a beta of 1.20. The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.19 and a current ratio of 4.22. The firm has a fifty day moving average of $36.67 and a two-hundred day moving average of $31.97.

AtriCure (NASDAQ:ATRC) last issued its earnings results on Thursday, July 23rd. The medical device company reported $0.18 earnings per share for the quarter. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. The business had revenue of $153.60 million for the quarter, compared to the consensus estimate of $151.80 million. During the same quarter in the previous year, the firm earned ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. On average, analysts forecast that AtriCure, Inc. will post 0.2 earnings per share for the current year.

Hedge Funds Weigh In On AtriCure

Hedge funds have recently bought and sold shares of the company. Geneos Wealth Management Inc. purchased a new stake in AtriCure during the second quarter worth $37,000. Smartleaf Asset Management LLC increased its position in shares of AtriCure by 59.8% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company’s stock valued at $46,000 after buying an additional 429 shares in the last quarter. Harbor Investment Advisory LLC acquired a new position in shares of AtriCure during the 2nd quarter worth $40,000. Allworth Financial LP acquired a new position in shares of AtriCure during the 2nd quarter worth $43,000. Finally, Fifth Third Bancorp purchased a new stake in shares of AtriCure in the 1st quarter worth about $51,000. 99.11% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have recently commented on ATRC. UBS Group reduced their price target on AtriCure from $55.00 to $50.00 and set a “buy” rating for the company in a report on Tuesday, July 28th. Wall Street Zen downgraded AtriCure from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 2nd. Canaccord Genuity Group upped their price target on shares of AtriCure from $53.00 to $55.00 and gave the stock a “buy” rating in a research note on Wednesday, May 6th. BTIG Research increased their price target on shares of AtriCure from $45.00 to $55.00 and gave the company a “buy” rating in a report on Monday. Finally, Citigroup reiterated a “market outperform” rating on shares of AtriCure in a report on Tuesday, July 21st. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $48.62.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.